Please login to the form below

Not currently logged in
Email:
Password:

Intellia

This page shows the latest Intellia news and features for those working in and with pharma, biotech and healthcare.

Vertex forges ties with gene editing firm CRISPR Therapeutics

Vertex forges ties with gene editing firm CRISPR Therapeutics

Celgene has also provided funding to CRISPR Thrapeutics, and earlier this year Novartis entered the fray after signing deals with Caribou Biosciences and Intellia Therapeutics that are focused on the development

Latest news

  • Novartis signs stem cell research pact with Intellia Novartis signs stem cell research pact with Intellia

    Novartis signs stem cell research pact with Intellia. Will work with the biotech start-up on creating new treatments. ... Intellia will gain access to certain Novartis intellectual property and technology for the development of its own product pipeline.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Earlier this month another CRISPR-Cas9 company, Intellia Therapeutics, raised $108m in an IPO to progress its early-stage programmes.

  • Deal Watch April 2016 Deal Watch April 2016

    265 . Intellia (US). Regeneron (US). Co-development &co-commercialisation. Discovery stage CRISPR/Cas platform for treatments of liver disease.

  • Deal Watch October 2015 Deal Watch October 2015

    companies. Other biotechs exploiting the CRISPR/Cas-9 technology for the development of therapeutics include Editas Medicine, Intellia Therapeutics and Caribou Biosciences; both Novartis and AstraZeneca have already developed collaborations in

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics